



DAFTAR PUSTAKA

1. Wedhanto S, Siregar UP. Duchenne Muscular Dystrophy. *Maj Kedokt Indones.* 2004;57:312–7.
2. Dooley J, Gordon KE, Dodds L, MacSween J. Duchenne muscular dystrophy: A 30-year population-based incidence study. *Clin Pediatr.* 2010;49(2):177–9.
3. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, *et al.* Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol.* 2010;9(1):77–93.
4. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, *et al.* Diagnosis and management of Duchenne muscular dystrophy , part 2 : implementation of multidisciplinary care. *Lancet Neurol.* 2010;9:177–89.
5. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. *Lancet Neurol.* 2003;2(12):731–40.
6. Sussman M. Duchenne muscular dystrophy. *J Am Acad Orthop Surg.* 2002;10(2):138–51.
7. Chapman MW. Chapman’s Orthopaedic Surgery 3rd Ed. In: Chapman MW, Szabo RM, Marder RA, Vince KG, Mann RA, Lanne JM, *et al.*, editors. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 4506-19.
8. Ropper AH, Brown RH. Adams and Victor’s Principles of Neurology, 8th Ed. New York: Mc Graw-Hill; 2005. p. 1214-7.
9. Parsons EP, Clarke AJ, Bradley DM. Developmental progress in Duchenne muscular dystrophy: Lessons for earlier detection. *Eur J Paediatr Neurol.* 2004;8(3):145–53.
10. Prior TW, Bridgeman SJ. Experience and strategy for molecular testing of Duchenne muscular dystrophy. *J Mol Diagnostics.* 2005;7(3):317–26.
11. Flanigan KM, Niederhausern AV, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. *Am J Hum Genet.* 2003;72(4):931–9.
12. Dent KM, Dunn DM, Niederhausern AC Von, Aoyagi AT, Kerr L, Bromberg MB, *et al.* Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. *Am J Med Genet.* 2005;298:295–8.
13. Canale ST, Beaty J. Campbell’s operative orthopaedics, 10th Eds. St.Louise: Mosby Inc; 2003. p. 1363-1373.
14. Verma S, Anziska Y, Cracco J. Review of Duchenne muscular dystrophy (DMD) for the pediatricians in the community. *Clin Pediatr.* 2010;49:1011–7.
15. Kemper AR, Wake MA. Duchenne muscular dystrophy : issues in expanding newborn screening. *Curr Opin Pediatr.* 2007;700–4.
16. Manzur A, Kuntzer T, Pike M, Av S. Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Review). *Cochrane Database Syst Rev.* 2010;(1):1–72.
17. Biggar WD. Duchenne Muscular Dystrophy. *Pediatr Rev.* 2006;27(3):83–7.



18. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, *et al.* Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. *Neurology*. 1989;39(4):475–81.
19. Moxley R, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, *et al.* Practice parameter corticosteroid treatment of Duchenne dystrophy. *Neurology*. 2005;64:13–20.
20. Pediatrics AA of. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. *Pediatrics*. 2005;116(6):1569–73.
21. Davidson ZE, Truby H. A review of nutrition in Duchenne muscular dystrophy. *J Hum Nutr Diet*. 2009;22(5):383–93.
22. Leung DG, Germain-Lee EL, Denger BE, Wagner KR. Report on the second endocrine aspects of duchenne muscular dystrophy conference December 1-2, 2010, Baltimore, Maryland, USA. *Neuromuscul Disord*. 2011;21(8):594–601.
23. Essen AJ Van, Verheij JBG, Reefhuis J, Fidler V, Jacobus H. The natural history of Duchenne muscular dystrophy . Analysis of data from a Dutch survey and review of age related events. 1997;49–63.
24. Eagle M, Baudouin S V, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. *Neuromuscul Disord*. 2002;12(10):926–9.
25. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur A. Corticosteroids for the treatment of Duchenne muscular dystrophy (Review). *Cochrane Database Syst Rev*. 2016;(5).
26. Davis J, Samuels E, Mullins L. Nutrition Considerations in Duchenne Muscular Dystrophy. *Nutr Clin Pract*. 2015;30(4):511–21.
27. Jackson CE. A Clinical Approach to Muscle Diseases. In: Seminars in neurology. 2008. p. 228–40.
28. Bianchi ML. Osteoporosis in children and adolescents. *Bone*. 2007;41(4):486–95.
29. Griffiths R, Edwards R. A new chart for weight control in Duchenne muscular dystrophy. *Arch Dis Child*. 1988;1256–8.
30. Varni JW, Limbers CA. The Pediatric Quality of Life Inventory: Measuring Pediatric Health-Related Quality of Life from the Perspective of Children and Their Parents. *Pediatr Clin North Am*. 2009;56(4):843–63.
31. Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M, *et al.* Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy (Systematic Review). *Cochrane Database Syst Rev*. 2017;1(1):1.
32. Morgenroth VH, Hache LP, Clemens PR. Insights into bone health in Duchenne muscular dystrophy. *Bonekey Rep*. 2012;1:1–11.
33. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. *Pediatr Cardiol*. 2005;26:768–71.
34. Nurhidayah I, Hendrawati S, Mediani HS, Adistie F. Quality of life of children living



- with cancer. *J Keperawatan Padjajaran*. 2016;4:45–59.
35. Lue Y-J, Chen S-S, Lu Y-M. Quality of life of patients with Duchenne muscular dystrophy: from adolescence to young men. *Disabil Rehabil*. 2017;39(14):1408–13.
 36. Party W, Marco M Di, Harrison L, Keddie A, Melville P, Tewnion J, *et al*. Duchenne Muscular Dystrophy Scottish Physiotherapy Management. *North Star*. 2012. 1-29 p.